You are here

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

September 5, 2017

  • RVT-802 is an investigational tissue-based therapy for primary immune deficiency associated with complete DiGeorge Syndrome
  • RVT-802 has also received Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and orphan drug designation from FDA
  • Enzyvant anticipates potential BLA filing in the first half of 2018
  • Morgan Molloy to join Enzyvant as Chief Commercial Officer

CLICK HERE to read the full press release



Disease Category:


Resource Category: